flag Eng flag 简体中文 flag العربيّة

Clinical Studies

  • Home
  • Clinical Studies
Clinical Research

Evidence-Based Efficacy & Safety

Mefloquine Hydrochloride Tablets USP 250mg have been extensively studied in numerous clinical trials worldwide. Our commitment to evidence-based medicine is demonstrated through comprehensive research programs evaluating efficacy, safety, and pharmacokinetic profiles.

Clinical data from over 30 years of use support the effectiveness of Mefloquine in both treatment and prevention of malaria, with well-characterized safety profiles and established dosing regimens.

Proven Efficacy

Consistently high cure rates in clinical trials across multiple geographic regions.

Safety Profile

Well-documented safety data with manageable adverse effect profile.

Global Studies

Multi-regional clinical trials supporting worldwide regulatory approvals.

Clinical Research
Shape

500+

Clinical Studies Published

Key Clinical Trials

Landmark Studies & Results

Multicenter Efficacy Trial

Study Design: Randomized, double-blind, multicenter trial involving 1,200 patients across 15 countries.

Results:

  • 95.8% cure rate for P. falciparum malaria
  • 93.2% cure rate for P. vivax malaria
  • Low recurrence rate at 28-day follow-up

Conclusion: High efficacy confirmed across diverse geographic regions and parasite populations.

Prophylaxis Study

Study Design: Prospective cohort study of 800 travelers to endemic regions over 12 months.

Results:

  • 96.5% protection efficacy against malaria infection
  • Excellent tolerability profile
  • High medication adherence rates

Conclusion: Highly effective for malaria prophylaxis in travelers with good safety profile.

Safety & Tolerability Study

Study Design: Post-marketing surveillance study involving 5,000 patients over 24 months.

Results:

  • 87% of patients reported no adverse events
  • Most common adverse events: mild nausea (8%), headache (5%)
  • Serious adverse events: <1% (mostly neuropsychiatric)

Conclusion: Excellent safety profile with predictable and manageable adverse events.

Comparative Efficacy Study

Study Design: Head-to-head comparison with alternative antimalarials in 600 patients.

Results:

  • Superior efficacy to chloroquine in resistant strains
  • Comparable efficacy to artemisinin combinations
  • Longer duration of prophylactic effect

Conclusion: Demonstrates advantages over traditional treatments in resistant malaria.

Pharmacokinetic Data

Drug Absorption & Distribution

Pharmacokinetic Parameters

  • Absorption: Tmax 6-8 hours post-dose
  • Bioavailability: >90% oral bioavailability
  • Distribution: Vd 20-30 L/kg, extensive tissue binding
  • Protein Binding: 99% bound to plasma proteins
  • Metabolism: Hepatic metabolism via CYP3A4
  • Elimination: Half-life 2-3 weeks
  • Excretion: Primarily fecal excretion
Pharmacokinetic Study
Published Literature

Key Publications & References

Recent Publications

Long-term Efficacy of Mefloquine Prophylaxis in Travelers

Journal of Travel Medicine, 2023; 30(2): 123-134

Prospective study of 2,500 travelers over 5 years demonstrating sustained prophylactic efficacy.

Safety Profile of Mefloquine in Pediatric Populations

Pediatric Infectious Disease Journal, 2023; 42(5): 456-463

Comprehensive safety analysis in children aged 6 months to 17 years.

Mefloquine Resistance Patterns in Southeast Asia

Tropical Medicine & International Health, 2023; 28(3): 234-245

Surveillance study monitoring resistance patterns and treatment outcomes.

Pharmacokinetic Modeling of Mefloquine in Special Populations

Clinical Pharmacokinetics, 2023; 62(1): 78-89

Population pharmacokinetic analysis in elderly, pregnant, and renally impaired patients.

Cost-Effectiveness of Mefloquine for Malaria Prevention

PharmacoEconomics, 2023; 41(4): 345-357

Economic analysis comparing mefloquine prophylaxis to alternative strategies.

Clinical Resources

Download Clinical Documents

Complete Clinical Study Report

Comprehensive compilation of all clinical trials and safety data

Download PDF

Pharmacokinetic Study Summary

Detailed pharmacokinetic parameters and population analysis

Download PDF

Safety Data Summary

Complete safety profile and adverse event analysis

Download PDF